Nanoprecise Sci Corp | $38,000,000 | (Mar 28, 2025)
Mendel | $35,000,000 | (Mar 28, 2025)
Galatea Bio Inc. | $25,000,000 | (Mar 28, 2025)
Certified by Founder
Lodge
OrsoBio
start up
United States
- Palo Alto, CA
- 08/11/2023
- Series A
- $60,000,000
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
- Industry Biotechnology Research
- Website https://orsobio.com/
- LinkedIn https://www.linkedin.com/company/orsobio/about/
MemryX Inc. | $44,000,000 | (Mar 28, 2025)
Mila Beauté | $2,160,000 | (Mar 28, 2025)
Lucky Beverage Co. | $14,200,000 | (Mar 28, 2025)
Taxo (YC S24) | $5,000,000 | (Mar 28, 2025)
BuildVision | $10,000,000 | (Mar 28, 2025)
Yutori | $15,000,000 | (Mar 28, 2025)
Nexthop AI | $110,000,000 | (Mar 27, 2025)
Topanga.io | $8,000,000 | (Mar 27, 2025)
Silna | $27,000,000 | (Mar 27, 2025)